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Summary
The interactions of huntingtin (Htt) with the SH3 do-
main- or WW domain-containing proteins have been
implicated in the pathogenesis of Huntington’s dis-
ease (HD). We report the specific interactions of Htt
proline-rich region (PRR) with the SH3GL3-SH3 do-
main and HYPA-WW1-2 domain pair by NMR. The re-
sults show that Htt PRR binds with the SH3 domain
through nearly its entire chain, and that the binding re-
gion on the domain includes the canonical PxxP-bind-
ing site and the specificity pocket. The C terminus of
PRR orients to the specificity pocket, whereas the N
terminus orients to the PxxP-binding site. Htt PRR
can also specifically bind to WW1-2; the N-terminal
portion preferentially binds toWW1, while the C-termi-
nal portion binds to WW2. This study provides struc-
tural insights into the specific interactions between
Htt PRR and its binding partners as well as the alter-
ation of these interactions that involve PRR, which
may have implications for the understanding of HD.
Introduction
Huntington’s disease (HD) is a dominant neurodegener-
ative disorder characterized by movement abnormali-
ties, cognitive impairment, and psychiatric disturbances
due to neuronal cell loss, especially in the basal ganglia
and the cerebral cortex (Martin and Gusella, 1986; Von-
sattel et al., 1985). Accumulating evidence supports the
finding that a polyglutamine (polyQ) expansion tract in
huntingtin (Htt), a ubiquitously expressed protein of yet
unknown function, is the cause of this disease (MacDon-
ald et al., 1993; DiFiglia et al., 1995).
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(X.-Z.Y.)Human Htt is a large multidomain protein of 3144
amino acid residues with a polyQ domain at the N termi-
nus (MacDonald et al., 1993). The polyQ domain ranges
from 11 to 34 glutamine residues in unaffected individ-
uals, whereas that of HD patients extends to 37 or
more glutamine residues (Bates et al., 2002). A proline-
rich region (PRR) containing 40 residues (normally resi-
dues 41–80) directly follows the polyQ domain in se-
quence (Figure 1A).
Recently, many investigations revealed that mutant
Htt with expanded polyQ impairs the normal interactions
of several proteins involved in gene transcription, traf-
ficking, endocytosis, and cell signaling (Goehler et al.,
2004; Harjes and Wanker, 2003; Li and Li, 2004). Thus,
it is speculative that HD neuropathology is related to
the interference of the normal function of cellular pro-
teins by the aberrant Htt protein (Landles and Bates,
2004; Li et al., 2003; Li and Li, 2004).
There are many Htt-interacting partners identified;
some contain Src homology 3 (SH3) or tryptophan
(WW) domains, such as SH3GL3/endophilin3 (Sittler
et al., 1998), protein kinase C and casein kinase sub-
strate in neurons 1 (PACSIN1/syndapin) (Modregger
et al., 2002), HYPA/FBP11 (Faber et al., 1998), PSD-95
(Sun et al., 2001), RasGAP (Liu et al., 1997), and CA150
(Holbert et al., 2001). Among them, SH3GL3 is reported
to be preferentially expressed in human brain and testis,
and its C-terminal SH3 domain is essential for the inter-
action with Htt PRR (Sittler et al., 1998). The characteris-
tics of the interaction between SH3GL3 and Htt and the
colocalization of these two proteins suggest that
SH3GL3 could be involved in the selective neuronal
cell death in HD (Sittler et al., 1998). SH3GL3 was also
found to bind to the shell of the Htt body, suggesting
that the SH3GL3-associated HD pathology may be
caused by sequestering the Htt inclusion bodies (Qin
et al., 2004). PACSIN1 has been implicated in clathrin-
mediated endocytosis (DiProspero et al., 2004), and its
abnormal binding behavior and altered intracellular dis-
tribution in pathological tissues suggest that it plays
a role during the early stages of the selective neuropa-
thology of HD (DiProspero et al., 2004; Modregger
et al., 2002). Human HYPA interacts with the N-terminal
region of Htt protein through its tandem WW domains,
as identified by yeast two-hybrid assay (Faber et al.,
1998; Passani et al., 2000). FBP11, the murine ortholog
of human HYPA, is one of the several proteins that
bind with formins involved in murine limb and kidney
development (Bedford, et al., 1997). FBP11 also partici-
pates in pre-mRNA splicing (Lin et al., 2004) and regula-
tion of N-WASP localization (Mizutani et al., 2004).
The involvement of PRR in the pathological process of
HD can also be observed from the fact that MW7 scFv,
a monoclonal antibody recognizing Htt PRR, signifi-
cantly inhibits aggregation as well as the cell death
induced by mutant Htt protein (Khoshnan et al., 2002).
Another observation indicates that removal of a series of
prolines adjacent to the polyQ tract in Htt blocks forma-
tion of the shell of the Htt body and redistributes seques-
tration of many vesicle-associated proteins, a process
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2004).
The typical PRR segment recognized by SH3 or WW
domains contains less than 10 amino acid residues
(Kay et al., 2000), and the molecular mechanism under-
lying the specific recognition has been elucidated and
reviewed (Ilsley et al., 2002; Musacchio, 2002; Sudol,
1996; Zarrinpar et al., 2003). However, many proteins,
such as Htt, formin (Bedford et al., 1997), and N-WASP
(Bompard and Caron, 2004), contain PRR far longer
than 10 residues. How these long PRRs recognize vari-
ous SH3 and WW domains remains largely unknown.
Obtaining the structural knowledge of the interaction
between Htt PRR and the SH3 or WW domain will be
the first step toward understanding how the abnormally
expanded polyQ tract interferes with the normal function
of cellular proteins that contain the SH3 or WW domain.
We have determined the solution structure of the SH3
domain of SH3GL3 and have assigned the backbone
resonances of the WW domain pair of HYPA by hetero-
nuclear NMR. Based on the structure, the binding spec-
ificities between Htt PRR and these domains have been
elucidated in detail. This study reveals that Htt PRR rec-
ognizes the SH3 domain and the WW domain pair with
high specificities, but with different mechanisms.
Figure 1. The N-Terminal, Central, and C-Terminal Portions of Htt
PRR Have Different Binding Preferences for the SH3 and WW
Domains
(A) The domain architecture of the N-terminal Htt protein and the
amino acid sequence of the PRR region. Six peptides corresponding
to different portions of Htt PRR were generated by peptide synthe-
sis. Pept-1, Pept-2, and Pept-3 were also generated and purified
as recombinant GST fusion proteins for pull-down assay.
(B) GST pull-down assay showing that the tandem WW domains of
HYPA-WW1-2 interact with GST-Pept-1 and GST-Pept-3, while
SH3GL3-SH3 and PACSIN1-SH3 only interact with GST-Pept-2
in vitro. The ‘‘Input’’ lane represents the band from 10% of the
amount of protein in each sample.Results
The Three Portions of Htt PRR Have Different
Preferences for the SH3 and WW Domains
To identify which portion of the Htt PRR region (residues
41–80) is responsible for the interaction with the SH3 or
WW domain, we subdivided the region into three pep-
tide parts, corresponding to the N-terminal (Pept-1),
central (Pept-2), and C-terminal (Pept-3) portions of
Htt PRR, respectively (Figure 1A). The three segmental
sequences were cloned and expressed as GST fusion
proteins for a pull-down assay. Figure 1B suggests
that SH3GL3-SH3 and PACSIN1-SH3 only bind to
Pept-2, not to Pept-1 or Pept-3, while HYPA-WW1-2
(the tandem domains of HYPA) binds to Pept-1 and
Pept-3, but not to Pept-2. This is consistent with the
previous study that an expanded Pept-2 specifically
binds with PACSIN1-SH3 (Modregger et al., 2002). The
results imply that the three portions of Htt PRR
have different binding affinities for the SH3 domain of
SH3GL3 or PACSIN1 and the tandem WW domains
of HYPA.
Solution Structure of the SH3GL3-SH3 Domain
To study the interaction between SH3GL3-SH3 and Htt
PRR in detail, we solved the structure of the SH3 domain
in solution by heteronuclear multidimensional NMR
techniques. A summary of the NMR experimental re-
straints for structure calculation and statistics is pre-
sented in Table S1 (see the Supplemental Data available
with this article online). All ten of the lowest-energy final
structures converge with an NOE or dihedral angle viola-
tion no greater than 0.3 A˚ or 5, respectively. The aver-
age root-mean-square deviations (rmsds) for the ten
structures for backbone and all heavy atoms are 0.64
and 1.76 A˚, respectively. Figure 2A depicts a superimpo-
sition of the ten lowest-energy structures and a ribbon
representation of one of the ten NMR structures. The so-
lution structure of SH3GL3-SH3 maintains a typical SH3
fold containing five b strands organized in an antiparallel
b barrel structure with a short 310 helix between the last
two b strands (Figure 2B). Similar to most SH3 fold do-
mains (Dalgarno et al., 1997), this structure also contains
two characteristic loops, namely, the RT loop between
b1 and b2 and the n-Src loop between b2 and b3. There
is also a broad pocket called the specificity pocket
Figure 2. 3D Solution Structure of the SH3 Domain from SH3GL3
(A) Backbone atom superposition of the final ten structures. The
structures are superimposed adopting residues 3–58.
(B) Ribbon diagram representation of the SH3 domain of SH3GL3.
The canonical PxxP-binding pocket is indicated in a circle, while
the specificity pocket between the RT loop and the n-Src loop is
also highlighted.
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1757Figure 3. Summary of the Chemical Shift Per-
turbations and Surface Mapping for Interac-
tions between SH3GL3-SH3 and Various Pro-
line-Rich Peptides
(A–F) The chemical shift perturbations of the
SH3 domain upon addition of (A) Pept-1, (B)
Pept-2, (C) Pept-3, (D) Pept-1-2, (E) Pept-2-
3, and (F) Pept-1-2-3 to a peptide:protein mo-
lar ratio of 8:1.
(G–J) The surface mapping of the significantly
perturbed residues (red) in the presence of
(G) Pept-1, Pept-2, or Pept-3; (H) Pept-1-2;
(I) Pept-2-3; and (J) Pept-1-2-3. The residues
with chemical shift changes larger than the
average are depicted on the surfaces of the
structure.
(K) The titration curves for Pept-1-2-3 binding
to the SH3 domain. By fitting the data to a bi-
molecular binding algorithm, the dissociation
constant (KD) of Pept-1-2-3 binding to
SH3GL3-SH3 is 680 6 80 mM.between these two loops. The canonical PxxP-binding
pocket is located on the hydrophobic patch that con-
tains a cluster of conserved aromatic residues (Tyr10,
Phe12, Trp38, and Tyr54) that are arranged adjacent
each other in a nearly parallel manner.
Binding Specificity of SH3GL3-SH3 with Htt PRR
To elucidate the binding specificity of SH3GL3-SH3 with
Htt PRR, several truncated peptides of Htt PRR (Fig-
ure 1A) were tested for interaction with the SH3 domain
by using the chemical shift perturbation method. Fig-
ure 3 shows the chemical shift mapping on the SH3 do-
main upon binding with various peptides. The effects on
some residues, such as Glu15 and Phe49, which have
amide resonances largely affected by the addition of
Pept-1 (Figure 3A), Pept-2 (Figure 3B), or Pept-3 (Fig-
ure 3C), are very similar. The significant residues for
these three titrations are mapped on the domain struc-
ture (Figure 3G), in which the significantly perturbed res-
idues are located in the RT loop of the SH3 domain. The
residues mostly affected by the addition of Pept-1-2
(Figure 3D) cover the canonical PxxP-binding site and
the specificity pocket between the RT loop and the
n-Src loop of SH3GL3-SH3 (Figure 3H). Moreover,
Pept-2-3 also exhibits similar binding properties with
Pept-1-2 (Figures 3E and 3I), though it possesses a dif-
ferent peptide sequence. The result that the three nona-
peptides, though having different sequences, bind tothe SH3 domain with similar binding behavior suggests
that their binding abilities may originate from prolines,
but not from the nonproline residues. A similar result is
also obtained from the binding of two double-portion
peptides (Pept-1-2 and Pept-2-3). It is likely that Pept-
1-2 and Pept-2-3 bind to the SH3 domain with similar
binding sites, but with different orientations. In addition,
binding of these short peptides, whether single portion
or double portions, to the SH3 domain is relatively
weak, whereas binding of Pept-2 to the SH3 domain is
a little stronger than that of Pept-1 and Pept-3 (Table
S2). This may explain why only the binding of Pept-2
with the SH3 domain has been identified by the less sen-
sitive experiment of pull-down assay (Figure 1B). These
results are consistent with the studies that recognition
of the SH3 domain by most short proline-rich peptides
is moderately weak and poorly selective, and that the
specificity pocket of the SH3 domain is favorable to pro-
line-rich peptide recognition (Santamaria et al., 2003).
For this reason, we speculate that the binding of these
short peptides to the SH3 domain is less specific, and
that it is the proline residue that contributes to the
binding.
As for the full-length PRR (Pept-1-2-3), its binding
causes perturbation on some additional residues, such
as Lys23, Glu24, and Asp26 (Figure 3F), which reside on
the opposite surface of the PxxP-binding pocket on the
SH3GL3-SH3 domain. Thus, the binding sites on the
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(A) Sequences of Pept-22-N and Pept-22-C. The Cys residue was attached to the N or C terminus of the peptide, and the MTSSL spin was spe-
cifically labeled to the thiol group of the Cys residue. N, Cys in the N terminus; C, Cys in the C terminus.
(B) Overlay of the HSQC spectra of the SH3 domain complexed with Pept-22-N-MTSSL (blue) and Pept-22-N (red).
(C) Overlay of the HSQC spectra of the SH3 domain complexed with Pept-22-C-MTSSL (blue) and Pept-22-C (red). The missing peaks due to the
paramagnetic effect are denoted by arrows.
(D) Mapping of the residues with peaks missing on the SH3GL3-SH3 domain structure. The residues with peaks missing induced by Pept-22-N-
MTSSL are colored in red, and the residues affected by Pept-22-C-MTSSL are colored in blue or red.domain structure cover the entire canonical PxxP-
binding site and the specificity pocket and perhaps its
opposite surface (Figure 3J). The saturation curves for
the chemical shift changes of three representative resi-
dues in SH3GL3-SH3 upon titration with Pept-1-2-3
are well fitted with a 1:1 stoichiometry (Figure 3K) and
give a dissociation constant (KD) ofw0.68 mM. Mutation
of Gln17 to Ala, which is located in the crucial RT loop,
causes the binding ability to be reduced by w3-fold
(KD = 2.2 mM). Taken together, the chemical shift pertur-
bation experiments indicate that the entire Pept-1-2-3 is
necessary for its specific binding to the SH3 domain.
When it is shortened, it would loss its binding affinity
(Table S2) and specificity (Figure 3). This binding speci-
ficity of Htt PRR for the SH3 domain might be required
for regulating SH3-mediated interactions (Li, 2005).
Orientation of Htt PRR Binding on the SH3 Domain
A spin-labeling NMR method (Mahoney et al., 2000) was
applied to identify the orientation of Htt PRR binding on
the surface of the SH3 domain. For ensuring that the
binding sites on the SH3 domain are affected by the
spin-labeled compound, we produced a pair of 22 resi-
due peptides, which contain not only the entire central
portion of Htt PRR, but also its several flanking amino
acids (Figure 4A), that were spin labeled with MTSSL
in either the N or C terminus. When the N-terminally
labeled peptide Pept-22-N-MTSSL binds to the SH3
domain, two crosspeaks in the HSQC spectrum corre-
sponding to Asp11 and Glu13 are nearly completely
eliminated (Figure 4B), indicating that the N terminus
of the peptide sterically contacts the SH3 domain nearthe Asp11 and Glu13 residues. As for Pept-22-C-MTSSL
binding, many resonances, even including those of
Asp11 and Glu13, are significantly affected by the spin
label, but most of the residues are located in the proxim-
ity of the specificity pocket of the SH3 domain (Fig-
ure 4C). This observation demonstrates that the C termi-
nus of the peptide contacts the SH3 domain near the
specificity pocket (Figure 4D). Taken together, these
findings indicate that Htt PRR exhibits a preferred bind-
ing mode on the SH3 domain (also see Figure 8A), and
that the orientation of PRR is consistent with that of
the Class II SH3 ligand (Mayer, 2001).
Evidence for the Specific Binding
from Intermolecular NOEs
On the basis of filtered-NOESY analysis on the SH3GL3-
SH3/Pept-1-2-3 complex (molar ratio of 1:1) (Figure 5A),
several NOE peaks from 7 residues in the SH3 domain
interacting with Pept-1-2-3 were unambiguously identi-
fied and assigned on the SH3 domain. Among the resi-
dues interacting with Pept-1-2-3 (Figure 5B), Gly8 and
Asn53 are located in the typical PxxP-binding site, while
Gln17 and Trp38 flank the specificity pocket. Surpris-
ingly, the residues Cys6, Ile28, and Val59 have also
been found to interact with Pept-1-2-3. These residues
are located on a concave surface corresponding to the
binding surface of Pex5p on the Pex13p-SH3 domain
(Douangamath et al., 2002; Kami et al., 2002). There is
a possibility that the extended residues in Pept-1-2-3
also contact the opposite surface of the SH3 domain
when it specifically binds to the PxxP-binding site and
the specificity pocket.
Binding Specificity of Huntingtin PRR
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SH3GL3-SH3/Pept-1-2-3 Complex
(A) Selected portion of an F1fF2e NOESY
spectrum of 13C/15N-SH3/unlabeled Pept-1-
2-3 complex (molar ratio of 1:1). Indicated
are the observed intermolecular NOEs be-
tween residues in the SH3 domain and
Pept-1-2-3 (mostly proline side chains).
These NOEs are the contributions of both
side chain atoms (Gln17, Trp38, and Asn53)
and backbone atoms (Cys6, Gly8, Ile28,
Trp38, and Val59) in the SH3 domain.
(B) Mapping of the contact surface on the
SH3GL3-SH3 domain structure with the resi-
dues (red) that are detected to have intermo-
lecular NOEs with Pept-1-2-3 in the complex.Backbone Dynamics of the HYPA WW Domain Pair
Since Htt PRR binds to the WW domain pair of HYPA, it
will be interesting to study how Htt PRR interacts with
this domain pair. The structure of the FBP11-WW1 do-
main has been elucidated (Pires, et al., 2005), but that
of WW2 and the domain orientation in the domain pair
remain unsolved. To explore whether these small WW
domains are orientationally flexible with respect to
each other in the WW domain pair of HYPA, we deter-
mined the relaxation rates (R1 and R2) and {
1H}-15N
NOEs for the WW1-2 domain pair (Figure S1). Generally,
large NOE values (>0.7) reflect slow internal motion,
whereas small values indicate substantial internal
motion and negative values are indicative of fully dis-
ordered regions (Bruschweiler, 2003). The average
NOE value of WW1 (residues 13–42) isw0.52, suggest-
ing that WW1 in the free state is marginally stable, which
has been proved by the following titration experiments.
WW2 (residues 54–83) is more poorly folded than WW1,
as indicated by its smaller NOE values (an average of
0.45). Moreover, the single WW1 domain is structured,
as the 1H-15N HSQC spectrum shows wide dispersion;
however, the single WW2 is fully disordered, as indi-
cated by severe line broadening and peak overlapping
(data not shown). The linker region (residues 43–53) ex-
hibits even faster internal motions than both domains,
and the average NOE value is only 0.33. A similar result
can also be obtained from the relaxation data of the
R2:R1 ratio (Figure S1). The different dynamics of WW1
and WW2 in the domain pair infers that they have differ-
ent properties for binding with PRR-containing partners.
Binding Specificity of the WW Domain Pair
with Htt PRR
To understand the binding properties of the HYPA WW
domain pair with Htt PRR in detail, we studied binding of
the three nonapeptides and Pept-1-2-3 from Htt PRR as
well as peptide PPTPPPLPP from the PRR of formin
(Bedford et al., 1997; Pires et al., 2005) by using thechemical shift perturbation method. The plots of the
chemical shift changes versus residue number of the
WW domain pair upon titration of various peptides at a
peptide:protein molar ratio of 8:1 are displayed in Fig-
ure 6. The addition of increasing amounts of the peptide
ligand PPTPPPLPP results in chemical shift changes of
a number of residues dispersed in both the WW1 and
WW2 domains (Figure 6A). During titration, the amide
resonances of some residues exhibit a little broadening
in the line widths. This line broadening may be due to
the chemical exchange at an intermediate time regime
between the ligand-free and -bound states. Notably,
the chemical shift changes for the residues in WW1 are
in some aspects similar to those for the corresponding
residues in WW2 at every titration point. This indicates
that both WW domains have similar binding capabilities
for peptide PPTPPPLPP. In other words, the two WW
domains have no selectivity for the peptide from formin,
which is consistent with the previous alanine-scanning
mutagenesis analysis (Bedford et al., 1997).
As for the peptides from Htt PRR, titration of Pept-1
causes chemical shift changes of a number of residues
in both domains, but more prominently in the WW1 do-
main (Figure 6B). During titration, the amide resonances
in WW1 exhibits large chemical shift changes with slight
line broadening, in contrast to the large broadenings ob-
served for the corresponding resonances in WW2 (Fig-
ure 7A). In particular, some amide resonances in WW2,
such as Ser61, Asp62, Tyr69, and Arg77, rapidly dis-
appear from the spectrum at the first titration point
and reappear at a peptide:protein ratio higher than 4:1.
Titration of Pept-2 results in only small or no chemical
shift changes of the residues in both domains, even at
a Pept-2:WW1-2 ratio of 8:1 (Figure 6C). There is no sub-
stantial line broadening in any of the resonances either
(Figure 7B). This indicates that Pept-2 has no or very
weak interaction with the WW1-2 domain pair, which is
consistent with the result from the pull-down experiment
(Figure 1B). Titration of Pept-3 also causes chemical
Structure
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ure 6D). During titration, some resonances in WW2,
such as Ser61 and Tyr69, exhibit increased peak intensi-
ties (Figure 7C), whereas the corresponding resonances
(Ser20 and Tyr28) in WW1 show no intensity change. In-
terestingly, titration of Pept-1-2-3 causes significant
chemical shift changes of many resonances in both do-
mains (Figure 6E). The resonances of these residues in
both domains rapidly disappear from the spectrum at
a peptide:protein ratio below 1:1 and reappear at a ratio
higher than 4:1 (Figure 7D). The intensities of these reap-
peared peaks at the last titration are significantly en-
hanced compared to the peaks in the ligand-free form.
This indicates that binding of Pept-1-2-3 leads WW1-2,
especially the WW2 part, to achieve a well-folded struc-
ture in the complex.
Upon binding with Pept-1, a number of resonances
(e.g., Thr16, Ser20, and Tyr28) in WW1 experience an
Figure 6. Chemical Shift Perturbation of the HYPA WW Domain Pair
upon Titration of Various Proline-Rich Peptides
(A–E) The chemical shift changes of WW1-2 versus its residue num-
ber are shown upon addition of peptide (A) PPTPPPLPP, (B) Pept-1,
(C) Pept-2, (D) Pept-3, and (E) Pept-1-2-3 to a peptide:protein ratio of
8:1. The negative data for WW2 in (B) represent the disappearance of
peaks due to line broadening.intermediate chemical exchange on the NMR timescale,
while the corresponding resonances undergo fast ex-
change upon binding with Pept-3 (Figures 7A and 7C).
As a rough approximation, tight binding might correlate
with slow ligand exchange, and weak binding might
correlate with fast exchange (Fielding, 2003). More-
over, the chemical shift changes of WW1 caused by
Pept-1 binding are large, in contrast to the small chem-
ical shift changes caused by Pept-3 binding in each titra-
tion step (Figure 7E). The titration curves of WW1 caused
by Pept-1 binding show that the binding tends to reach
saturation at a lower Pept-1 concentration than the con-
centration of Pept-3 in the curves of WW1 caused by
Pept-3 binding. Collectively, these results demonstrate
that Pept-1 binds to WW1 more tightly than Pept-3.
Since WW2 is not as stable in the ligand-free state as
WW1, which is indicated by the dynamics analysis (Fig-
ure S1), it is possible that WW2 undergoes confor-
mational exchange on the NMR timescale even in the
ligand-free state. Upon peptide binding, the chemical
exchange between the ligand-bound and -free states
makes it complicated to compare how WW2 binds to
Pept-1 and Pept-3. Upon addition of Pept-1, a number
of resonances in WW2 undergo chemical shift change
and line broadening (Figure 7A). Some of them (e.g.,
Ser61 and Asp62) disappear and finally reappear at the
later titrations; some (e.g., Tyr69 and Glu83) do not reap-
pear even at the last titration point (peptide:protein ratio
of 8:1). However, upon addition of Pept-3, the corre-
sponding peaks in WW2 do not disappear, but their
chemical shifts do change (Figure 7C). Interestingly, the
intensities of these peaks increase considerably upon
binding. This indicates that, in contrast to Pept-1, a small
amount of Pept-3 could transform WW2 from a relatively
unstable state to the rather stable bound state. From
this aspect, Pept-3 is a preferential ligand for WW2 bind-
ing. The titration curves for chemical shift changes of
WW2 upon addition of Pept-2 or Pept-3 clearly indicate
that WW2 preferentially binds to Pept-3, not Pept-2
(Figure 7F). Taken together, these findings show that
WW2 in the ligand-free state is less stable than WW1
in the form of tandem domains. Pept-1 is preferential
to WW1 binding, while Pept-3 is preferential to WW2
binding; however, Pept-2 has no or very weak binding
capability for both WW1 and WW2. Thus, Pept-1-2-3
should exhibit a preferred binding mode on the HYPA
WW domain pair (also see Figure 8B).
Discussion
Multiple Binding Sites of the SH3GL3-SH3 Domain
Currently, three different ligand-binding sites on diverse
SH3 domains have been identified. The first is the
canonical PxxP-binding site that is constructed by the
conserved aromatic residues. The second is the speci-
ficity pocket between the RT loop and the n-Src loop,
such as the binding site of p67phox SH3(C) for the
a-helical portion of the p47phox tail peptide (Kami et al.,
2002). The third site, analogous to the binding site of
Pex5p on the Pex13p-SH3 domain, is located on the
opposite concave surface of the specificity pocket
consisting of the b1 and b2 strands and the C terminus
(Barnett et al., 2000; Douangamath et al., 2002; Kami
et al., 2002). Our data provide convincing evidence to
Binding Specificity of Huntingtin PRR
1761Figure 7. Summary of the Spectral Perturbations for Interactions between the HYPA WW Domain Pair and Various Peptides
(A) Overlay of a representative region of the 1H-15N HSQC spectra of HYPA-WW1-2 upon titration of Pept-1. The traces show the peak move-
ments from free peptide (black) to a peptide:protein ratio of 8:1 (purple). The changes of some typical peaks in the WW1 and WW2 domains
are indicated by labeling the residues. Most peaks in WW1 (such as T16, S20, Y27, and Y28) undergo chemical shift changes, while many peaks
in WW2 (S61, D62, Y69, R77, and E83) tend to disappear.
(B) Titration of Pept-2 to HYPA-WW1-2. Pept-2 has no or very little effect on the peaks in both WW1 and WW2 domains.
(C) Titration of Pept-3 to HYPA-WW1-2. Some peaks in WW1 (T16 and S20) exhibit chemical shift changes, while some peaks in WW2 (S61, D62,
Y69, and R77) exhibit line broadening.
(D) Titration of Pept-1-2-3 to HYPA-WW1-2. Many peaks in both domains are significantly affected by the addition of Pept-1-2-3. Most of the
peaks first disappear and then reappear due to the intermediate exchange. The intensities of some of the reappeared peaks at the last titration
(purple) are significantly enhanced compared to the peaks in the ligand-free form (black).
(E) Plot of weighted average chemical shift changes for three typical residues in WW1 (T16, S20, and Y28) versus the concentration of Pept-1
(red), Pept-2 (green), and Pept-3 (blue).
(F) Plot of average chemical shift changes for residues in WW2 (Y59, Y69, and R77) versus the concentration of Pept-2 (green) and Pept-3 (blue).
Due to the large line broadening, the titration curve for chemical shift changes of the residues in WW2 upon the addition of Pept-1 to WW1-2 is not
included.support that Htt PRR specifically binds to the SH3 do-
main, and that the binding sites include the canonical
PxxP-binding site and the specificity pocket (Figure 8A).
Since the PRR chain is much longer than the canonical
SH3 ligands, it is likely that it can contact the SH3 do-
main on the third site, as indicated by the results of the
intermolecular NOE experiment. The C terminus of
PRR orients to the specificity pocket, whereas the N ter-
minus orients to the PxxP-binding site, which is consis-
tent with what is observed in the Class II SH3 ligand
(Mayer, 2001). This kind of binding mode may allow
PRR motifs (generally in the PPII helix) to bind with var-
ious SH3 domains that are more diverse and selective.Characteristics of the Interaction of the HYPA
WW Domain Pair
Many proteins possess arrays of multiple WW domains;
it is likely that the tandem WW domains cooperate with
each other to achieve further specific recognition. To our
knowledge, Htt PRR is the first example reported as a li-
gand for binding of the WW domain pair. The N-terminal
portion of Htt PRR preferentially binds to WW1, while the
C-terminal portion binds to WW2; however, the central
portion remains unoccupied (Figure 8B). Up to date,
only two structures of the tandem WW domain pair,
Prp40 (Wiesner et al., 2002) and Su(dx) (Fedoroff et al.,
2004), have been solved. In the case of HYPA, both
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wide dispersion of amide resonances in the 1H-15N
HSQC spectrum. These domains, especially WW2, are
not as stable as those in the ligand-bound states. The
current study also provides insights into the dynamics
and ligand recognition of the WW domain pair.
Alteration of the Interactions Involving PRR
Has Implications for the HD Pathology
Since the aberrant interactions involved in Htt PRR and
its SH3 domain- or WW domain-containing partners
might be associated with the pathology of HD, it is inter-
esting to know how the polyQ tract alters the normal in-
teraction between Htt PRR and the SH3 or WW domain.
Our current result showing that the N terminus of Htt
PRR, occurring after the polyQ domain, is critical for
binding to the SH3 domain and the WW domain pair
implies that the specific interactions are susceptible
to the length of the polyQ tract. In the Htt-interacting
partners, all of the SH3 domain- or WW domain-contain-
ing partners, except PSD-95, bind more tightly to Htt
with elongated polyQ stretch (Li and Li, 2004). It is pos-
sible that the elongated polyQ stretch makes the entire
PRR region more accessible to these SH3 domain- or
WW domain-containing partners and thus enhances
their binding.
Since Htt PRR is proximal to the polyQ tract, it is likely
that alteration of the interactions involving PRR is
associated with the HD pathology. The expanded polyQ
tract makes the PRR region more available to the WW-
containing proteins or to MW7, a monoclonal antibody
recognizing Htt PRR, and significantly inhibits aggrega-
tion as well as the cell death induced by the mutant Htt
protein (Khoshnan et al., 2002). In addition, removal of
a series of prolines adjacent to the polyQ region in Htt
blocks formation of the shell of the Htt body and redis-
tributes the sequestration of many vesicle-associated
proteins, a process that may be related to neuronal dys-
function (Qin et al., 2004). Considering that interactions
involving Htt PRR are susceptible to polyQ length (Feany
and La Spada, 2003; Li et al., 2003; Sugars and Rubinsz-
tein, 2003), we speculate that the alteration of these
specific interactions is one of the substantial causes
for HD pathology.
Figure 8. Schematic Representation of the Specific Interactions of
Htt PRR with the SH3 Domain and the WW Domain Pair
(A and B) In the SH3 domain, almost all of the residues of the PRR
chain contribute to SH3 binding, and the binding sites on the SH3
domain include the typical PxxP-binding site and the specificity
pocket. The interaction is oriented such that the C terminus of PRR
points toward the specificity pocket, while the N-terminus is proximal
to the PxxP-binding site. In the case of the WW domain pair, two WW
domains cooperatively bind to Htt PRR; WW1 specifically binds to
the N-terminal portion, and WW2 binds to the C-terminal portion.Experimental Procedures
Protein Expression and Purification
The encoding sequence for the SH3GL3-SH3 domain, correspond-
ing to residues 285–344 of SH3GL3, was amplified via PCR and was
cloned into the pET-22b expression plasmid by using the NdeI/XhoI
cloning sites. The SH3 sequence was renumbered from 285–344 to
1–60, which is hereinafter used for describing the SH3 domain.
The plasmid was transformed into E. coli BL21 (DE3). Cells harbor-
ing the plasmid were grown at 37C. When OD600 reached w0.6,
SH3GL3-SH3 expression was induced by adding IPTG to a final con-
centration of 0.1 mM. The culture was then shaken for 10 hr at 25C.
After cell lysis, the protein was purified through a nickel-NTA column
(QIAGEN), followed by a 16/40 Superose 12 column (Amersham
Pharmacia). 15N- and 15N/13C-labeled SH3GL3-SH3 proteins were
prepared by using the M9 minimal medium containing 15NH4Cl
and/or 13C6-D-glucose as the sole nitrogen and/or carbon resource,
respectively.
The encoding sequence of the WW1-2 domain, corresponding to
residues 136–224 of HYPA/FBP11, was amplified via PCR and was
cloned into the pET-3a plasmid by using the NdeI/BamHI sites.
The WW1-2 sequence was renumbered from 136–224 to 1–89, which
is hereinafter used for describing the HYPA-WW1-2 domain. The
plasmid was transformed into E. coli BL21 (DE3). Cells containing
the plasmid were grown at 37C until an OD600 ofw0.8 was reached.
Expression was induced by adding IPTG to a final concentration of
0.1 mM. The culture was then shaken for 10 hr at 25C. The protein
was purified sequentially by heat denaturation, ion-exchange chro-
matography on a Q-Sepharose Fast Flow column and gel filtration
on a 16/60 Superdex 75 column (Amersham Pharmacia). The encod-
ing sequences of the WW1 and WW2 domains, corresponding to
residues 10–42 and 51–83 of WW1-2, respectively, were amplified
via PCR and were cloned into the pGBTNH plasmid by using the
BamHI/XhoI cloning sites (Bao et al., 2006). The respective plasmid
was transformed into E. coli BL21 (DE3). Cells harboring each plas-
mid were grown at 37C. When OD600 reachedw0.8, WW1 or WW2
expression was induced by adding IPTG. After cell lysis, the super-
natant was loaded onto a nickel-NTA column (QIAGEN). After wash-
ing, followed by on-column thrombin cleavage for removing the GB1
tag, the protein was eluted and subjected to chromatography on
a 16/40 Superose 12 column (Amersham Pharmacia).
Synthesis of Proline-Rich Peptides
The peptides (PPTPPPLPP, Pept-1, Pept-2, Pept-3, Pept-1-2, Pept-
2-3, and Pept-1-2-3) were obtained from automatic solid-phase
peptide synthesis on 2-Cl-Trt resin by using the FMOC strategy.
The N-terminal amino group and the C-terminal carboxyl group of
the peptides were retained unmodified. After release of the peptides
from the resin by using AcOH/TFE/DCM, the peptides were purified
by reverse-phase HPLC by following standard protocols involving
a water/acetonitrile solvent system containing 0.1% trifluoroacetic
acid. Pooled fractions of the pure peptides were lyophilized and
analyzed by electrospray mass spectrometry to verify identity and
homogeneity.
Spin Labeling
For producing the two peptides Pept-22-N and Pept-22-C, the
genes encoding these peptides were chemically synthesized and in-
serted into pGBTNH vectors by using the BamHI/XhoI cloning sites
(Bao et al., 2006). Then, the cysteine-containing peptides were
obtained according to the method for production of the WW1 and
WW2 domains described above. To label the peptides with MTSSL
((1-oxyl-2,2,5,5-tetramethyl pyrroline-3-methyl)methanethiosulfo-
nate, Toronto Research Chemicals, Canada), a 10-fold molar excess
of MTSSL was added to each peptide in a 20 mM sodium phosphate
buffer containing 50 mM NaCl (pH 8.0). The mixture was incubated
for longer than 12 hr at 4C, and the free compound was removed
by size-exclusion chromatography. The resulting peptides were ver-
ified by mass spectrometry.
GST Pull-Down Assay
The generation of GST fusion proteins containing short peptides
corresponding to the N-terminal, central, and C-terminal portions of
Htt PRR was carried out as described previously (Modregger et al.,
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17632002). For pull-down assay, the GST fusion proteins were added to
the glutathione Sepharose 4B beads (Amersham Biosciences) in
a PBS buffer (10 mM sodium phosphate, 100 mM NaCl, 5 mM di-
thiothreitol), and the suspension was agitated at 4C for 30 min.
The GST fusion protein-bound beads were washed three times in
the same buffer to remove any unbound protein. An equimolar
amount of SH3 or WW1-2 was added, and the suspension was agi-
tated at 4C for an additional 30 min. The resin was recovered by
centrifugation, and, after excessive washing, the sample was resus-
pended in the sample buffer and subjected to SDS-PAGE in a 15%
gel, followed by Coomassie staining.
NMR Spectroscopy
To solve the solution structure of the SH3GL3-SH3 domain, a
15N/13C-labled sample containing w1 mM protein in a phosphate
buffer (10 mM sodium phosphate, 100 mM NaCl, 5 mM dithiothreitol,
and 0.05% w/v sodium azide [pH 6.0] in 92% H2O/8% D2O or 100%
D2O) was used for NMR experiments. All NMR data acquisition was
carried out at 27C on a Varian INOVA 600 spectrometer equipped
with three RF channels and a triple-resonance pulsed-field gradient
probe. The backbone and side chain 1H, 15N, and 13C resonances
were assigned based on the spectra of 3D HNCO, HNCACB,
CBCA(CO)NH, H(CCO)NH, C(CO)NH and 3D 15N TOCSY-HSQC,
HCCH-TOCSY. NOE distance restraints for structure calculations
were obtained from 3D 15N-edited NOESY and 13C-edited NOESY
(aliphatic 13C regions). Intermolecular NOEs between SH3GL3-SH3
and Pept-1-2-3 were obtained from 2D-filtered/edited NOESY ex-
periments as described (Peterson et al., 2004).
For HYPA-WW1-2, 15N- or 15N/13C-labeled sample containing
w1 mM protein in a phosphate buffer (10 mM sodium phosphate,
100 mM NaCl, 5 mM dithiothreitol, and 0.05% w/v sodium azide
[pH 6.0] in 92% H2O/8% D2O or 100% D2O) was used for NMR exper-
iments. The backbone resonances were assigned based on the
spectra of 3D HNCO, HN(CA)CO, HNCACB, CBCA(CO)NH and 3D
15N TOCSY-HSQC, 15N-edited NOESY.
Structure Calculation and Analysis
The NMRPipe software suite (Delaglio et al., 1995) was applied to
process the NMR data, and NMRView (Johnson and Blevins, 1994)
software packages were used for resonance peak picking and
data analysis. The CNS program (Brunger et al., 1998) with the
ARIA module (Nilges et al., 1997) was adopted to assign NOE peaks
and to calculate structures. The protein structures were assessed by
using PROCHECK (Laskowski et al., 1996) and were displayed by
the MOLMOL program (Koradi et al., 1996). Hydrogen bond re-
straints (two per hydrogen bond) were generated by a combination
of H/D exchange data, medium-range NOEs, and chemical shift
index. Backbone dihedral angle restraints (f and 4) were derived
from the TALOS program (Cornilescu et al., 1999). For SH3GL3-
SH3, the restraints used for structural calculation are summarized
in Table S1. The structural calculation in combination with iterative
NOE peak assignments was performed for 9 cycles, and a total of
200 structures were finally obtained. Ten structures of the lowest
energies, which exhibit no NOE violation > 0.3 A˚ and no dihedral
violation > 5, were selected.
Determination of Backbone Relaxation Parameters
All 15N relaxation data for WW1-2 were acquired at 25C by using 2D
proton-detected heteronuclear NMR experiments implementing the
standard pulse sequences (Farrow et al., 1994). A recycle delay of
1.5 s was used for measuring R1 and R2 relaxation rates. The spectra
for measuring the {1H}-15N heteronuclear NOEs were recorded with
a 2 s relaxation delay, followed by a 3 s period of proton saturation.
In the absence of proton saturation, the spectra were recorded by
a relaxation delay of 5 s. The relaxation rates, R1 and R2, were ob-
tained by fitting the measured peak intensities to a two-parameter
function by using a nonlinear least-square fitting algorithm (Press
et al., 1992) and were presented as a ratio of R2 to R1. The steady-
state {1H}-15N NOE enhancements were calculated as the ratio of
peak intensity in spectra recorded with or without proton saturation.
NMR Titration
NMR titrations for SH3GL3-SH3 were performed at 27C, and those
for HYPA-WW1-2 were performed at 25C. 15N-labeled SH3 orWW1-2 was dissolved to a concentration of 0.25 mM in the above-
mentioned NMR buffer, and the proline-rich peptides were added
stepwise to give the peptide:protein molar ratios ranging from 0:1
to 8:1; each step was monitored by 2D 1H-15N HSQC spectrum.
The combined average chemical shift changes were calculated as
Ddave = ([0.17DdN]
2 + [DdH]
2)1/2, where DdH and DdN are the chemical
shift changes in the 1H and 15N dimensions, respectively. The titra-
tion curves were fitted assuming a bimolecular binding event as de-
scribed (Liu et al., 1999). Dissociation constants (KD) were obtained
by analyzing the chemical shift changes of three typical residues for
SH3GL3-SH3 or its Q17A mutant upon addition of each peptide.
Supplemental Data
Supplemental Data include onefigureand two tables and areavailable
at http://www.structure.org/cgi/content/full/14/12/1755/DC1/.
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